SGMO are now $3 a share. I am going to load it up and hold them for 5 years until someone find out a better way to edit Genes.

Sangamo BioSciences is engaged in the research, development, and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes. Co. has a proprietary technology platform that is based on the engineering of a naturally occurring class of proteins referred to as zinc finger DNA-binding proteins (ZFPs). Also, ZFPs may be engineered to create zinc finger nucleases, or ZFNs , which can be used to cut genomic DNA at a pre-selected sequence location, enabling ZFN-mediated disruption of genes that are responsible for disease pathology, correction of genes that contain disease-causing mutations, or the targeted addition of a selected DNA sequence.